Registration Dossier
Registration Dossier
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 214-291-9 | CAS number: 1119-97-7
Endpoint summary
Administrative data
Key value for chemical safety assessment
Genetic toxicity in vitro
Description of key information
In vitro mutagenicity testing in bacteria on C12 TMAC and C16 TMAC
In vitro chromosome aberation test in mammalian cells on C16 TMAC
In vitro mutation test in mammalian cells on C12 TMAC
See attached read-across justification to tetradonium bromide attached in section 13
Endpoint conclusion
- Endpoint conclusion:
- no adverse effect observed (negative)
Additional information
From read-across to genotoxicity data on structurally closely related substances there is no concern for mutagenic effects in relation to tetradonium bromide. No in vivo testing is warranted.
Justification for selection of genetic toxicity endpoint
In a weight of evidence approach, data on both C12 and C16
alkyltrimethylammonium chloride are used for prediction of the genetic
toxicity of the C14 alkyltrimethylammonium bromide.
Short description of key information:
Data on cetrimonium (C16) chloride from testing in salmonelle
typhimurium with and without S9 was negative.
Data on dodecyl(C12)trimethylammonium chloride from testing in
salmonelle typhimurium with and without S9 was negative.
Data on cetrimonium (C16) chloride from testing in in vitro chromosome
aberration test (OECD 473) was negative.
Data on dodecyl(C12)trimethylammonium chloride from testing in an in
vitro mouse lymphoma assay (comparable to OECD 476) with and without S9
was negative.
Data on dodecyl(C12)trimethylammonium chloride from testing in an in
vitro rat hepatocytes UDS assay (comparable to OECD 482) was negative.
In vivo test with dodecyl(C12)trimethylammonium chloride in rats in a
bone marrow chromosome aberration test (comparable to OECD 475) was
negative.
Endpoint Conclusion: No adverse effect observed (negative)
Justification for classification or non-classification
Tetradonium bromide should not be classified in relation to mutagenicity.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.
